Internal Legal Brief
Prepared for Transmission to External Securities and Healthcare Regulatory Counsel
This memorandum analyzes whether SaludCoin (SLUD) constitutes a "security" under the Howey test and its progeny, and whether SLUD earn triggers implicate the Medicare Anti-Kickback Statute (AKS). Counsel is requested to (1) validate the securities analysis and issue a risk-stratified opinion, and (2) advise on AKS safe harbor structuring before any pilot launch involving Medicare or Medicaid beneficiaries.
Our preliminary analysis indicates that SLUD is well-structured to defeat securities classification under Howey, most strongly on the "expectation of profits" prong. However, the AKS exposure is more significant and requires affirmative safe harbor structuring — particularly for earn events tied to Medicare-covered services.
The following facts from the SaludCoin technical specification (Salud Capital Internal Technical Spec, April 2025) are material to both analyses and are summarized here for counsel's reference. The full specification is transmitted as Exhibit A.
Earn mechanism: SLUD is minted exclusively by the earnReward() function, callable only by the oracle wallet holding MINTER_ROLE. The oracle fires only upon cryptographically verified health actions: MinuteClinic visits (trigger type 0), Rx prescription refills (trigger type 1), annual Medicare wellness visits (trigger type 3), and vaccinations (trigger type 4). SLUD cannot be purchased, airdropped speculatively, or issued for investment activity of any kind.
Transfer restriction: The _update() override in SaludCoin.sol enforces that any transfer where both from and to are non-zero addresses (i.e., any peer-to-peer transfer) requires that at least one party be in the transferWhitelist. The whitelist is admin-controlled and populated only with CVS, Aetna, and Medicare supplement service contract addresses. SLUD cannot be traded on any secondary market.
Redemption: The redeem() function burns SLUD and calls creditBeneficiary() on the destination service contract, providing a healthcare service credit. SLUD is redeemable only against approved healthcare services — it is never redeemable for cash, stablecoins, or other cryptocurrency. The redemption rate is administratively set and does not fluctuate with market conditions.
No supply cap / no scarcity mechanism: SLUD has no maximum supply. Each earn event produces a protocol-determined amount independent of other users' activity. There is no mechanism by which aggregate user behavior affects the value or redemption power of any individual's SLUD balance.
The Supreme Court's four-prong test in SEC v. W.J. Howey Co., 328 U.S. 293 (1946) defines an "investment contract" as: (1) an investment of money, (2) in a common enterprise, (3) with a reasonable expectation of profits, (4) derived from the efforts of others. The SEC has consistently applied this test to digital tokens. All four prongs must be satisfied for SLUD to constitute a security; failure of any single prong defeats classification.
| Prong | Standard (Howey & Progeny) | SLUD Facts | Result | Confidence |
|---|---|---|---|---|
|
I. Investment of Money
Broad reading: tangible/intangible value exchanged for an interest
|
The Court has extended "investment" beyond cash to include services and labor (Uselton v. Commercial Lovelace Motor Freight, 940 F.2d 564). The SEC's Framework (Apr. 2019) acknowledges non-monetary investment. Any exchange of value may satisfy Prong I. | SLUD cannot be purchased. Earn triggers are verified healthcare behaviors — MinuteClinic visits, Rx refills, Annual Wellness Visits. No fiat, crypto, or other consideration is exchanged for SLUD. User health actions are behavioral, not investment acts. Counsel should address whether health actions constitute "investment" under the broad Uselton reading. | Not Met Primary basis for non-security finding |
High |
|
II. Common Enterprise
Horizontal or vertical commonality
|
Circuits split: horizontal commonality (Seventh, Ninth) requires pooling of investor funds with pro-rata sharing of returns. Vertical commonality (Fifth, Eleventh) requires fortunes of investors tied to promoter's success. Either form may suffice depending on jurisdiction. | No pooling of user funds — SLUD is minted individually per-user per-action. Users' SLUD balances are independent; one user's earn does not dilute another's. No profit-sharing arrangement. Salud's operational success does not affect the redemption value of SLUD (fixed by contract). However, if Salud becomes insolvent, the redemption mechanism fails — weak vertical commonality argument may exist. | Weakly Met Insolvency risk = indirect tie |
Medium |
|
III. Expectation of Profits
Capital appreciation or income from the investment
|
United Housing Foundation v. Forman, 421 U.S. 837 (1975): expectation of profits means financial return on investment, not mere "use value." Profit must flow from price appreciation or distribution, not from consumption. International Brotherhood of Teamsters v. Daniel, 439 U.S. 551 (1979): mandatory pension contributions not securities because no profit expectation independent of employment. | SLUD has no market price. No exchange listing. No secondary market (transfer-restricted by contract). Redemption rate is fixed administratively — no capital appreciation is possible. SLUD provides only "use value" — a discount on services the user would otherwise pay for. This is functionally identical to a CVS ExtraCare coupon or a Walgreens Cash reward. No profit motive is possible. | Not Met Strongest independent ground |
Very High |
|
IV. Efforts of Others
Investor's return depends on promoter's managerial efforts
|
SEC v. Glenn W. Turner Enterprises, 474 F.2d 476 (9th Cir. 1973): "efforts" must be the "undeniably significant ones, those essential managerial efforts which affect the failure or success of the enterprise." Purchaser's own significant efforts may defeat this prong. | SLUD value (its service credit purchasing power) depends on CVS/Aetna contractual commitments — not on Salud's ongoing managerial efforts. The user's own health behaviors generate the earn. No "essential managerial efforts" by Salud determine whether SLUD is worth more or less — the redemption rate is contractually fixed. | Not Met User effort, not Salud's |
High |
SLUD fails Prongs I, III, and IV of the Howey test on the current design. Prong II presents a weak but non-trivial insolvency-based argument for vertical commonality, but this alone cannot establish security status. Because all four prongs must be met, SLUD is unlikely to be classified as a security. Counsel is requested to confirm this analysis and identify any circuit-specific or SEC framework nuances that may alter the conclusion.
To the extent any component of SLUD could be characterized as a "note" (a written promise to deliver services), Reves v. Ernst & Young, 494 U.S. 56 (1990) applies a "family resemblance" test examining: (1) motivation of seller and buyer, (2) plan of distribution, (3) reasonable expectations of the investing public, and (4) existence of alternative regulatory scheme. SLUD satisfies none of the indicia of a security note: the buyer's motivation is healthcare access (not investment); there is no plan of distribution to the general investing public; no reasonable person would view SLUD earn as an investment; and healthcare loyalty rewards are subject to extensive FDA, CMS, and state insurance regulation.
The following no-action letters and SEC guidance provide directly applicable precedent. Counsel should evaluate whether SLUD's structure is sufficiently analogous to seek a no-action letter or rely on existing guidance.
Scenario: Even with on-chain transfer restrictions, if a secondary OTC market for SLUD develops (e.g., users sell healthcare service credits through informal channels), the SEC may revisit classification. The transfer guard in SaludCoin.sol technically prevents on-chain trading but does not prevent off-chain informal markets.
Mitigation: (1) The redeem() function burns SLUD and credits only the wallet of the original earner — making off-chain informal transfers economically valueless since the buyer cannot redeem. (2) Counsel should confirm whether the burn-on-redeem mechanism, combined with holder-identity verification via SaludID (soulbound), effectively prevents informal market formation.
Request 1: Provide a formal opinion letter on SLUD security status under Howey, with circuit-specific analysis for jurisdictions where Salud intends to operate (focus: IL, TX, FL, CA, NY).
Request 2: Evaluate feasibility of a TurnKey Jet-type no-action request. If recommended, draft the submission. Identify any post-2019 SEC guidance that modifies the TurnKey/Pocketful framework.
Request 3: Confirm whether SLUD's earn mechanism (health behaviors, not money) satisfies the Uselton "investment" analysis definitively, or whether a grey area exists that the no-action letter should address preemptively.
Request 4: Advise on the Ripple risk — specifically, whether any SLUD allocations to team members, advisors, or CVS/Aetna as part of commercial agreements could be characterized as institutional securities sales.
The federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), prohibits knowingly and willfully offering, paying, soliciting, or receiving "any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind" to induce or reward the referral of items or services covered by a federal healthcare program, or to induce or reward the purchase of items or services reimbursable under a federal healthcare program.
The fundamental problem: SLUD awarded when a Medicare beneficiary completes a MinuteClinic visit (billed to Medicare), fills an Rx covered by Part D, or completes a Medicare Annual Wellness Visit (a covered preventive benefit) constitutes "remuneration" — specifically a "thing of value" — provided in connection with a federal healthcare program-covered service. Even if SLUD has no cash value, it has service value (redeemable for healthcare credits). OIG has historically interpreted "remuneration" extremely broadly to include any item of value, regardless of form.
Intent is not required for per se AKS violation — only "knowing and willful" conduct is required, and offering incentives to Medicare beneficiaries has been found sufficient to meet that standard.
The following safe harbor analysis evaluates each potentially applicable safe harbor under 42 C.F.R. Part 1001.952.
| Safe Harbor | Citation | Requirements Summary | SLUD Fit | Analysis |
|---|---|---|---|---|
|
Discount Safe Harbor
42 C.F.R. § 1001.952(h)
|
§ 1001.952(h) | Discount or price reduction offered to buyer at time of sale; properly disclosed on cost report or claim; reflects actual transaction price. Applies to sellers of items/services covered by federal healthcare programs. | Partial | SLUD-as-discount could work if: (a) SLUD redemption is treated as a price reduction on a CVS/Aetna service, (b) the discount is properly reflected on any Medicare/Medicaid claim, and (c) the discount is not contingent on referrals. The challenge: SLUD is earned on one transaction and redeemed on a different future transaction — not a "discount at time of sale." OIG may not extend the safe harbor to deferred-credit arrangements. Requires affirmative structuring and counsel opinion. |
|
Waiver of Beneficiary Copayments
§ 1001.952(k)
|
§ 1001.952(k) | Waivers of Medicare Part A/B copays only if based on genuine financial need (after good-faith income investigation) or under insurance arrangement. Routine waivers not protected. | Poor Fit | SLUD is not a copayment waiver — it is an independent service credit. This safe harbor does not apply unless SLUD is specifically structured as a copay subsidy for demonstrated financial hardship, which would require means-testing the earn program and conflicts with the broad-access positioning. |
|
Promotional Gift (Nominal Value)
§ 1320a-7a(a)(5) exception
|
42 U.S.C. § 1320a-7a(a)(5)(A) | Items/services of "nominal value" (OIG guidance: ≤$15/item; ≤$75/year aggregate per beneficiary) provided for free are excepted from the civil monetary penalty for inducements. OIG Advisory Bulletin 2002. | Partial | Applicable only if SLUD redemption value does not exceed the $15/$75 thresholds. If a MinuteClinic visit earns 100 SLUD redeemable for a $10 service credit, a single visit may fit under the per-item threshold. Annual aggregate for active users (multiple Rx refills, AWV, vaccines) likely exceeds $75. This safe harbor may cover incidental earn events but cannot cover the full program. |
|
Improved Quality of Care / Care Coordination Exception
§ 1320a-7a(a)(5)(B)
|
42 U.S.C. § 1320a-7a(a)(5)(B) (ACA § 6402) | Remuneration not likely to influence site/source of services; promotes access to care; improves quality, health outcomes, or efficiency. OIG has narrowly interpreted. Requires that the remuneration not induce unnecessary utilization. | Partial | SLUD for Medicare AWV and Rx adherence directly promotes preventive care and medication compliance — core objectives of this exception. However: (a) OIG requires the remuneration not likely influence site-of-service (SLUD tied to CVS/MinuteClinic may be seen as inducing CVS utilization); (b) there must be no evidence of inducing unnecessary services. The AWV and Rx adherence triggers are the strongest fit; MinuteClinic general visit triggers may be weaker. |
|
Personal Services Safe Harbor
42 C.F.R. § 1001.952(d)
|
§ 1001.952(d) | Covers payments for legitimate personal services between entities and individuals. Requires set in advance, fair market value, commercially reasonable, written agreement ≥1 year. | Poor Fit | Does not apply to benefit-to-beneficiary remuneration. Relevant only if CVS/Aetna were paying Salud for advisory or management services — does not address the beneficiary-facing SLUD earn issue. |
|
OIG Advisory Opinion Process
42 C.F.R. Part 1008
|
§ Part 1008 | OIG issues advisory opinions on whether proposed arrangements constitute grounds for sanctions. Binding only on requestor. Process takes 60–150 days. OIG has addressed wellness incentive programs in prior advisory opinions. | Strongly Recommended | Analogous OIG Advisory Opinions: OIG AO 08-09 (wellness program rewards to Medicare beneficiaries for completing health assessments — permitted under conditions); OIG AO 11-12 (care coordination rewards). SLUD's earn structure maps closely to wellness incentive programs approved by OIG. An advisory opinion should be sought before any Medicare beneficiary pilot. |
If Salud Vault is distributed through Aetna Medicare Advantage channels, the CMS Medicare Marketing Guidelines (MMG), 42 C.F.R. § 422.2268, impose additional restrictions. Medicare Advantage organizations are prohibited from offering "gifts or other remuneration as part of marketing" and from "using gifts or other remuneration to influence enrollment decisions." SLUD earn tied to MA plan enrollment or MA-covered services at CVS/MinuteClinic may be treated as a marketing inducement prohibited under the MMG, independent of the AKS analysis. Counsel should advise on whether the Salud Vault CVS distribution arrangement, if co-branded with Aetna MA, constitutes "marketing" subject to the MMG.
For SLUD earn events involving Medicaid managed care organizations (MCOs) — particularly Dual Eligible Special Needs Plans (D-SNPs) identified in the SaludPass architecture — each state Medicaid program has independent anti-kickback rules that may be more restrictive than the federal AKS. Illinois (305 ILCS 5/8A-3), Texas (Tex. Hum. Res. Code § 36.002), and Florida (§ 409.920, Fla. Stat.) each impose state law penalties independent of federal AKS liability. Counsel should provide a multi-state analysis for initial pilot states.
Request 1: Provide a formal analysis of SLUD earn under the AKS, evaluating all applicable safe harbors and the Civil Monetary Penalty statute's nominal value exception (42 U.S.C. § 1320a-7a(a)(5)). Identify the minimum necessary structural modifications to achieve a defensible safe harbor position.
Request 2: Evaluate Approach B (wellness incentive structure) and identify whether an OIG Advisory Opinion is achievable and at what cost/timeline. Identify the closest analogous advisory opinions (recommend: OIG AO 08-09, OIG AO 11-12, OIG AO 12-06) and advise on distinguishing features.
Request 3: Analyze CMS Medicare Marketing Guidelines applicability to the Aetna co-branded CVS distribution channel. Specifically: does CVS retail distribution of Salud Vault constitute "marketing" of Medicare Advantage plans subject to MMG restrictions?
Request 4: Provide a multi-state Medicaid anti-kickback analysis for initial pilot states (recommend: Illinois, Texas, Florida). Identify state-specific disclosure or consent requirements.
Request 5: Evaluate whether Approach D (annual $75 nominal value cap enforced by smart contract) provides sufficient legal protection to permit the Medicare population to participate in the pilot phase without an OIG Advisory Opinion.
SLUD is well-designed to avoid securities classification. The three independently sufficient grounds — (1) no money invested, (2) no expectation of profits, and (3) no dependence on Salud's essential managerial efforts — align closely with the TurnKey Jet and Pocketful of Quarters no-action precedents. The structure is meaningfully stronger than most wellness loyalty token arrangements that have been reviewed by SEC staff. The primary residual risk is secondary market emergence and any non-earn allocation of SLUD to insiders. Counsel is requested to validate this analysis and advise on the cost-benefit of formal SEC no-action relief.
The AKS exposure is real and must be addressed before any Medicare or Medicaid beneficiary pilot. The most pragmatic near-term path is Approach D (nominal value cap to $75/year, enforced on-chain) combined with an immediate OIG Advisory Opinion filing under the wellness incentive framework. The Medicare Annual Wellness Visit and Rx adherence earn triggers are the highest-value use cases and the most legally defensible if structured as wellness program incentives — but they require affirmative OIG guidance before deployment at scale. The MinuteClinic general visit trigger for Medicare patients is the highest AKS risk and should be excluded or capped to nominal value pending OIG opinion.
A compliant SLUD program serving commercial insurance and self-pay patients can launch without blocking regulatory approvals, subject to receipt of the securities opinion letter (Action 1) and state commercial insurance anti-inducement analysis. The Medicare/Medicaid beneficiary program should be deferred until: (a) Approach D smart contract cap is implemented (14–21 days); and (b) OIG Advisory Opinion is on file (90–150 days). This sequencing allows the commercial pilot to proceed immediately while the regulatory track for Medicare runs in parallel.